Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Px-104 in NAFLD
NCT01999101Phase 2Completed
- Sponsor
- Phenex Pharmaceuticals AG
- Start
- Oct 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of px-102 in non-alcoholic fatty liver disease (NAFLD), sponsored by Phenex Pharmaceuticals AG. Primary endpoint: Safety and tolerability at 28 days. Started Oct 2013; status: completed.
02
Drugs
px-102
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT01999101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999101.